Farmacie pro praxi. 2023;19(1):25-30 | DOI: 10.36290/lek.2023.003
Age-related macular degeneration - new treatment options
- Oční klinika, Lékářská fakulta v Hradci Králové, Univerzita Karlova
Age-related macular degeneration (AMD) is the most common cause of vision loss in people over the age of 65 in developed countries. In most patients, a dry form of AMD is noted, which gradually progresses. Choroidal neovascular membrane is the main sign of wet form of AMD which is present in 10 % of patients approximately. AMD develops because of an interaction between genetic and lifestyle factors of patients. The treatment of the choice of the wet form of AMD is intravitreal anti-vascular endothelial growth factor injections, in the case of the dry form of AMD we can choose dietary supplements with lutein and haemorheopheresis. Treatment of the dry form of AMD with intravitreal administration of complement inhibitors is currently under investigation. An essential prerequisite for successful treatment is early diagnosis and especially early initiation of the treatment.
Keywords: age-related macular degeneration, anti-VEGF drugs, complement inhibitors, hemorheopheresis.
Accepted: February 17, 2023; Published: March 3, 2023 Show citation
References
- Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004;44:17-39.
Go to original source... - Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study: I. Outline and major prevalence findings. Am J Epidemiol. 1977;106(1):17-32. Go to original source...
- Augood CA, Vingerling JR, de Jong PTVM, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol. 2006;124(4):529-35. Go to original source...
- Alberti WE, Richard G, Sagerman RH. Age-Related Macular Degeneration: Current Treatment Concepts. Berlin: Springer - Verlag Berlin Heidelberg; 2001. Go to original source...
- Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-ethnic Study of Atherosclerosis. Ophthalmology. 2006;113(3):373-80. Go to original source...
- Delcourt C, Diaz J-L, Ponton-Sanchez A, et al. Smoking and age-related macular degeneration: the POLA Study. Arch Ophthalmol. 1998;116(8):1031-5. Go to original source...
- Zweifel SA, Spaide RF, Curcio CA, et al. Reticular pseudodrusen are subretinal drusenoid deposits. Ophthalmology. 2010;117(2):303-12. Go to original source...
- Age-related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta karotene and zinc for age-related macular degeneration and vision loss. AREDS Report 8. Arch Ophthalmol 2001;119:1417-36. Go to original source...
- Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic agerelated macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75 (4): 216-30. Go to original source...
Go to PubMed... - Liao DS, Grossi FV, El Mehdi D, et al. Complement c3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmol. 2020;127:186-195. Go to original source... Go to PubMed...
- Goldberg R, Heier JS, Wykoff CC, et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest Ophthalmol Vis Sci. 2022;63(7):1500.
- Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of complement factor 3 in geographic atrophy with ngm621: phase 1 dose-escalation study results. Am J Ophthalmol. 2021;235:131-142. Go to original source...
- Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmol. 2021;128:576-586. Go to original source... Go to PubMed...
- Klingel R, Fassbender C, Fassbender T, et al. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-basedmedicine. Transf Apher Sci. 2003;29:71-84. Go to original source...
- Rencová E, Bláha M, Studnička J, et al. Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis. J Ophthalmol. 2015;359747. Go to original source...
- Brunner R, Widder RA, Walter P, et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial. Retina. 2000;20(5):483-91. Go to original source...
- Narayanan R, Kuppermann BD, Jones C, et al. Ranibizumab. Nat Rev Drug Discov. 2006;5(10):815-6. Go to original source... Go to PubMed...
- SÚKL, indikační omezení úhrady ranibizumabu [Internet]. Available from: https://www.sukl.cz/modules/medication/detail.php?code=0210255&tab=prices.
- Studnička J. Ranibizumab (Lucentis) v léčbě věkem podmíněné makulární degenerace. Čes a slov Oftal. 2009;65(3):107-111.
- Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol. 2007;143(4):679-80. Go to original source...
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med. 2006;355(14):1432-44. Go to original source...
- Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-70. Go to original source... Go to PubMed...
- SÚKL, indikační omezení úhrady afliberceptu [Internet]. Available from: https://www.sukl.cz/modules/medication/detail.php?code=0193696&tab=prices
- Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-48. Go to original source...
- Ohji M, Takahashi K, Okada AA, et al. ALTAIR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial. Adv Ther. 2020;37(3):1173-87. Go to original source...
- Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antipody fragment VEGF inhibitor rth258 for neovascular age-related macular degeneration: A randomized controlled study. Ophthalmology. 2016;123(5):1080-9. Go to original source...
- Tietz J, Schmid G, Konrad J, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56:1501.
- SÚKL, indikační omezení úhrady brolucizumabu [Internet]. Available from: https://www.sukl.cz/modules/medication/detail.php?code=0238813&tab=prices.
- Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72-84. Go to original source...
- Heier JS, Khanani AM, Quezada Ruiz C, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. Go to original source...